How Blue Cross and BCN are handling prior authorizations for Makena following FDA announcement

In an April 6 news release,** the U.S. Food and Drug Administration announced it has withdrawn its approval of Makena^® (hydroxyprogesterone caproate), HCPCS codes J1726 and J1729. The decision also applies to generic Makena products.

This means Makena and its generic products are now unapproved and can’t lawfully be distributed in interstate commerce.

For Blue Cross Blue Shield of Michigan and Blue Care Network commercial members, here’s how we’re handling prior authorizations for Makena:

• We’re honoring prior authorization requests that have already been approved for this medical benefit drug through their end dates.
• We’re denying prior authorization requests submitted for dates of service on or after April 6, 2023.

These changes apply to:

• All Blue Cross and BCN commercial members
• All versions of Makena, including compounded and generic versions

We’ve updated the pertinent drug lists to reflect this change.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.